Feb 26, 2023 / 10:00PM GMT
Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria
Feb 26, 2023 / 10:00PM GMT
=====================
Corporate Participants
=====================
* Anthony S. Marucci
Celldex Therapeutics, Inc. - Founder, President, CEO & Director
* Diane C. Young
Celldex Therapeutics, Inc. - Senior VP & Chief Medical Officer
* Sarah Cavanaugh
Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration
* Tibor Keler
Celldex Therapeutics, Inc. - Founder, Chief Scientific Officer & Executive VP
=====================
Conference Call Participants
=====================
* Evan Porter Taddeo
Guggenheim Securities, LLC, Research Division - Research Analyst
* Kristen Brianne Kluska
Cantor Fitzgerald & Co., Research Division - Analyst
* Samuel Evan Slutsky
LifeSci Capital, LLC, Research Division - Senior Research Analyst
* Thomas Jonathan Smith
SVB Securities LLC, Research Division - Senior MD of Immunology and Metabolism &
Celldex Therapeutics Inc
(NAS:CLDX)
$
25.43
0.04 (0.16%)
Market Cap: 1.69 Bil
Enterprise Value: 883.77 Mil
PE Ratio: 0
PB Ratio: 2.07
GF Score: 63/100 Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria Transcript
Feb 26, 2023 / 10:00PM GMT
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot